66 patients with central neuropathic pain due to multiple sclerosis (MS) were randomly assigned to receive either cannabis-based medicine (CBM) through oromucosal spray or placebo for 4 weeks. Participants were assessed on pain severity, sleep disturbances, the impression of change, the incidence of adverse events, cognitive abilities, mood, and MS-related disability at the beginning and end of the study. Results demonstrated that oromucosal administration of CBM was effective in improving pain, sleep disturbance compared to placebo. The incidence of adverse events, cognitive abilities, mood, and disability were similar compared to placebo.